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Abstract
The Molluscum Contagiosum Virus (MCV) causes a common persistent, skin
infection. Two MCV immune evasion molecules, MCV MC159 and MC160 contain
tandem death effector domains (DEDs). DEDs are found in several host proteins
including pro-apoptotic proteins Fas-associated Death Domain (FADD) and procaspase-8
and are well characterized in innate immune signaling. MC159 blocks apoptosis induced
by both Tumor Necrosis Factor (TNF) and the Fas ligand (FasL) and inhibits activation
the host pro-inflammatory transcription factor nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) (Shisler, 2001; Murao and Shisler 2005). MC160, however,
does not inhibit apoptosis, but does dampen TNF-induced NF-κB activation (Shisler,
2001; Nichols and Shisler, 2006). Both MC159 and MC160 inhibit activation of type I
interferons induced via the mitochondrial antiviral signaling (MAVS) pathway, an
important innate signaling network that senses the presence of a viral double-stranded
RNA (dsRNA) and induces an interferon (IFN) response. MC159 interacts with the
protein kinases TBK-1 and IKKε. However, the molecular mechanism of MC160 is not
well understood. When expressed independently, both the C-terminal domain of MC160
as well as the first DED were reported to inhibit TBK-1 induced IRF-3 activation,
whereas the second DED was dispensable (Randall et al., 2013).
The goal of the current project is to identify the molecular mechanism through
which MC160 inhibits activation of type I IFNs. We characterized the ability of MC160
constructs to inhibit MAVS- and TBK-1 induced activation of type I IFN. When
expressed independently neither MC160 DED1 nor DED2 blocked activation the IFN-β
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enhancer to the extent of full-length or the MC160 construct that expresses both DEDs.
Our current analysis suggests that both DED1 and DED2 are required to fully inhibit
activation of type I interferons.

x

Introduction
Molluscum Contagiosum Background
The Molluscum Contagiosum Virus (MCV) is a double-stranded (ds) DNA virus
that belongs in the Poxviridae family. Since the eradication of smallpox, MCV remains
the only poxvirus to exclusively infect humans. MCV infects keratinocytes and mucosal
membranes, causing benign lesions that can persist for months to years in otherwise
healthy individuals (Chen et al., 2013). MCV neoplasms are characterized by painless,
white or flesh-colored dome-shaped papules with a shallow depression in the middle, that
average from 2 to 5mm in size (Hughes et al., 2013). The infection is not typically lethal;
however, in immunocompromised patients, the infection can be much more severe (Chen
et al., 2013). Fatalities have occurred due to a secondary bacterial infection in those with
weakened immune systems (Cotton et al., 1987). MCV primarily spreads through skin to
skin contact, making children the most susceptible however, adults may contract the virus
as well through sexual contact. MCV can also spread by autoinoculation or fomites. In
2010 there were 122 million cases reported, making MCV the third most common skin
infection in children (Shisler, 2015).
Currently, there is no FDA approved cure or treatment for MCV lesions.
Although the lesions will usually resolve on their own, some patients elect treatment
(Shisler, 2015). The most common treatments of pediatric MCV include the use of
cantharidin, imiquimod, curettage, cryotherapy, retinoids, and cidofovir (Coloe and
Morrell, 2009). Therapies may help treat the viral infection. However, current MCV
treatments are not 100 % effective and are associated with problems, such as anxiety,
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painful treatments and scarring that lasts even after the infection has resolved.
Cantharidin, the most common therapy, is applied topically and is absorbed by the
epidermal cell membranes, thus activating neutral serine proteases eventually leading to
acantholysis and intraepidermal blistering and nonspecific lysis of skin (Bertaux et al.,
1988; Moed et al., 2001).
The persistence of MCV is most likely due to dampening of host innate immune
responses through the production of MCV immune evasion molecules. However, the
pathogenicity of MCV infections remains poorly understood. MC lesions present
themselves as inflamed (I-MC) and non-inflamed (NI-MC). Histological studies suggest
regression of MCV-induced lesions is observed in patients with I-MC, but not NI-MC
(Vermi et al. 2011). NI-MC lesions do not provoke an inflammatory response in hosts
and seem to have poor apoptotic responses, presumably because caspase-3 is inactive. In
contrast, Vermi et al. reported active caspase-3 in I-MC lesions and apoptotic cell death
(Vermi et al., 2001). Additionally, nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-𝜅B) activation and translocation into the nucleus followed by type I
interferon (IFN) activation have been observed in cells surrounding I-MC lesions.
However, neither have been observed in cells surrounding NI-MC lesions (Vermi et al.,
2011). The varying responses may suggest that MCV encodes for immune evasion
molecules, which may be found in NI-MC lesions. MCV immune evasion molecules
inhibit several host immune responses, such as apoptosis. Because MCV cannot be
cultured in mammalian cells or studied in animal models, it is especially difficult to
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determine which proteins are essential for MCV to maintain its ability to impede host
innate immune responses.
Molluscum Contagiosum Virus Immune Evasion Strategy
Like all poxviruses, MCV replicates within the cytoplasm of host cells. To ensure
successful replication, MCV encodes a myriad of immune evasion molecules, which
dampen host immune responses. For example, the MC54 protein is a critical binding
protein of Interleukin-18 (IL-18) that is secreted when cells are infected and inhibits the
pro-inflammatory activity of IL-18 (Xiang and Moss, 2003). MC148 is a viral chemokine
which inhibits chemotaxis by binding to CCR8 and CxC12𝛼 (Luttichau et al., 2000; Jin et
al., 2011). MC007 is a protein that is expressed in the mitochondria and stimulates
cellular proliferation by inhibiting retinoblastoma protein (pRb) (Mohr et al., 2008). The
MC66 protein inhibits apoptosis induced by ultraviolet light and hydrogen peroxide
(Shisler et al., 1998). MC132 inhibits NF-𝜅B activation by targeting p65 for degradation
(Brady et al., 2015). Similarly, MC005 interacts with the IKK complex and inhibits NF𝜅B activation, by NF-𝜅B essential modulator (NEMO) (Brady et al., 2017). MC163
prevents mitochondrial membrane permeabilization (MMP), an important apoptotic event
controlled by tumor necrosis factor-alpha (TNF-𝛼) or carbonyl cyanide 3chlorophenylhydrazone (CCCP) (Beaury et al., 2017). MC159 inhibits activation of the
extrinsic apoptotic pathway and inhibits the activation of NF-𝜅B (Shisler and Moss,
2001; Murao and Shisler, 2005). MC160 inhibits TNF-𝛼 induced NF-𝜅B activation
(Nichols and Shisler 2006).
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MCV Protein
MC007

Function
Inhibits pRb

Mechanism
Binds pRb

MC54

Inhibits IL-18

Binds IL-18

MC148

Inhibits chemotaxis

Binds CCR8 and CxC12𝛼

MC66

Inhibits apoptosis

MC132

Inhibits NF-𝜅B activation

Blocks H202 and UV-induced
apoptosis
Induces degradation of p65

MC005

Inhibits NF-𝜅B activation

MC159

Inhibits apoptosis, IFN-
activation, and activation of
NF-𝜅B

MC160

Inhibits NF-𝜅B activation
Inhibits IFN- activation

MC163

Inhibits apoptosis

NEMO-regulated I𝜅B kinase
activation
Apoptosis: Binds procaspase-8,
FADD, TRAF2
NF-𝜅B: interacts with the IKK𝛾
IFN-: Binds TBK1 and IKK𝜀
Binds procaspase-8, FADD, and
Hsp90

Localizes to mitochondria to
prevent MMP
Table 1. Known functions of the MCV Immune Evasion Molecules
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Molluscum Contagiosum Virus MC159 and MC160 Proteins
MC159 and MC160 are viral homologs that belong to a group of proteins known
as viral FADD-like IL-1β–converting enzyme (FLICE)-like inhibiting proteins (v-FLIPs)
(Randall and Shisler, 2013). A distinctive feature of v-FLIPS is the presence of tandem
death effector domains (DEDs) (Figure 2). Proteins containing DEDs affect numerous
signaling pathways, including apoptotic cell death and activation of pro-inflammatory
transcription factors IRF3 and NF-𝜅B (Garvey et al., 2002; Shisler, 2014). The
expression of MC159 inhibits Fas- and TNF-𝛼-induced apoptosis and interacts with fasassociated protein with death domain (FADD) and procaspase-8, ultimately inhibiting
apoptosis (Bertin et al., 1997; Shisler and Moss, 2001). MC159 expression also
suppresses TNF-𝛼-induced activation of NF-𝜅B by directly interacting with the IKK𝛾
regulatory subunit and TNF receptor-associated factor 2 (TRAF 2) (Randell et al., 2012).
NF-𝜅B is a transcription factor that is known to regulate host immune responses during
an infection and is activated by TNF-𝛼. When TNF-𝛼 binds to TNFR-1 the signalsome,
containing TNFR1-associated death domain protein (TRADD), TRAF2, and receptioninteracting protein (RIP), is formed (Chen et al., 2002). The signalsome then goes on to
recruit and activate the IKK complex composed of IKKβ, IKKα, and a regulatory
subunit, IKKγ. As long as NF-𝜅B is inactive, it will remain in the cytoplasm sequestered
by I𝜅B𝛼. Upon activation of the IKK complex by pathogens (PAMPs) or proinflammatory cytokines (TNF-𝛼), the activated IKK complex phosphorylates I𝜅B𝛼
protein (Hayden et al., 2004). Phosphorylation of I𝜅B𝛼 leads to its ubiquitination and
degradation, thereby freeing NF-𝜅B allowing for translocation into the nucleus,
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subsequently activating target genes, such as type I IFNs (Hayden et al., 2004).
Much is known about the homology, binding partners and function of MC159. In
contrast, little is known about the binding partners and function of the MC160 protein.
MC160 expression prevents TNF-𝛼-induced NF-𝜅B activation by interacting with
procaspase-8 and heat shock protein 90 (Hsp90), thereby inhibiting the IKK complex.
(Nichols and Shisler, 2006; Nichols and Shisler, 2009). Even with the ability MC160 has
to bind to FADD and procaspase-8 through DEDs, the MC160 protein does not inhibit
apoptosis (Shisler and Moss, 2001). Recently, both MC159 and MC160 proteins were
reported to inhibit activation of type I IFNs (Randall et al., 2013; Balachandran et al.,
2007).
Activation of Type I Interferons
When the immune system is compromised, the first line of defense is triggered by
the innate immune system. Pattern-recognition receptors (PRRs) recognize foreign viral
RNA or DNA, also called pathogen-associated molecular patterns (PAMPs) and
subsequently activates immune signaling cascades, such as the RIG-I/IRF3 pathway
(Bender et al., 2015). The innate immune response is responsible for activating type I
IFNs, which are crucial to hosts during viral infections. The innate immune system
utilizes type I IFNs, such as IFN- and IFN-𝛼, which have three important functions.
IFNs activate antimicrobial states in infected cells and neighboring cells to stop the
infection from spreading. IFNs promote antigen presentation and natural killer cell
functions. Finally, IFNs activate adaptive immunity, thus activating highly specific B cell
and T cell responses as well as immunological memory (Ivashkiv et al., 2014).
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During a poxvirus infection, dsRNA accumulates in the cytoplasm and is detected
by PRRs retinoic acid inducible gene 1 (RIG-I) and melanoma differentiation-associated
gene 5 (MDA5), triggering an innate immune response. RIG-I and MDA5 form a
complex with a mitochondria-localized adaptor protein, mitochondrial antiviral signaling
(MAVS) protein (Jacobs et al., 2014). The complex activates a MAVS “signalosome”
consisting of TRAF3, TRAF6, TRAF family member associated NF-𝜅B (TANK)
activator and TRADD (Jacobs and Coyne, 2013). The complex ultimately leads to
activation of type I IFNs and pro-inflammatory cytokines by activation of TANK binding
kinase 1 (TBK-1) and IKK𝜀, which in turn phosphorylates and activates the transcription
factor interferon regulatory factor 3 (IRF3) (Figure 1). Virus-induced phosphorylated
IRF3 is one of several host transcription factors that induces IFN- production. IFN-, in
turn, signals through the Janus Kinase/Signal Transducers and Activators of
Transcription (JAK/STAT) pathway, thereby stimulating the production of IRF7. The
positive feedback regulation of IRF7 on IFN-𝛼 and other IFN-stimulated genes (ISGs) is
critical to fully activate type I IFNs (Honda and Taniguchi, 2006). The MAVS signaling
pathway also activates NF-𝜅B, which translocates into the nucleus to help drive the
expression of type I IFNs (Bender et al., 2015). NF-𝜅B and IRF3 work synergistically to
induce the production of type I IFNs along with other inflammatory cytokines in response
to a viral infection.

7

Figure 1: dsRNA is a by-product of a Poxvirus infection, and acts as a PAMP. Upon
infection, PRRs detect dsRNA, thereby initiating a signaling cascade by MAVS to fight
off the viral infection.
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MC159 and MC160 dampen MAVS-mediated activation of type I IFNs
MC159 and MC160 antagonize MAVS signaling. MC159 disrupts activation of
type I IFNs by binding to TBK-1 and IKK𝜀. Although MC160 inhibits IFN- activation,
the molecular mechanism and binding partner of the MC160 protein remains unknown.
To better understand the molecular mechanism by which MC160 expression inhibit IFN
signaling, a panel of MC160 truncation mutants were generated (Nichols and Shisler
2009) (Figure 2). Previously, Randall et al. reported MC160 expression inhibited TBK-1induced IRF3 activation (Randall et al., 2013). When transiently transfected into cells,
every MC160 construct had the ability to inhibit IRF3-regulated luciferase activity, with
the exception of MC160D2 (Randall et al., 2013). Because the IFN--enhancer element
contains binding sites for several transcription factors including, NF-𝜅B, IRF3 and IRF7,
we wanted to determine if the same regions of MC160 were required to inhibit activation
of type I IFNs. To this end, the MC160 truncation mutants were characterized by their
ability to inhibit MAVS and TBK-1-induced IFN- luciferase activity. MC160 constructs
were expressed in 293T cells along with either pMAVS or pTBK-1. Results were
analyzed through various luciferase assays observing relative fold change in MAVS- or
TBK-1-mediated IFN- luciferase activity. Protein expression was confirmed via
immunoblots. Notably, the constructs containing both DEDs together, MC160 and
MC160N, showed the most inhibition of MAVS- and TBK-1-induced IFN- luciferase
activity, suggesting that both DEDs may be required to inhibit this pathway.

9

Figure 2: MCV MC160 wild type and truncation mutant proteins (Nichols & Shisler,
2009). The full length MC160 protein contains two tandem death effector domains
(DEDs) at residues 5-79 for DED1 and 97-175 for DED2, as well as a C-terminal region
at residues 225-371. An HA-tag was engineered into the N-terminal region of each
construct for protein detection.
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Methods and Materials
DNA Preparations
DH5𝛼 Escherichia Coli (E.Coli) bacteria carrying recombinant DNA were
isolated using the PureYield Plasmid Miniprep system (Promega). Bacteria were cultured
in 3mLs of Luria Broth (LB) supplemented with 100g/mL of ampicillin. After
incubating the bacteria in an incubator shaker at 37C at 225 rpm for 17-20 hours, the
bacteria were placed into a 1.5mL microcentrifuge tube, and centrifuged at 14,000 rpm
for 1 minute. The supernatant was discarded, and the pellet was resuspended in 600L of
1x Tris-EDTA buffer (TE). The plasmid DNA was harvested by following the Promega
miniprep protocol by adding 100L of cell lysis buffer, followed by 350L of
neutralization solution buffer and centrifuged for 3 minutes at 14,000 rpm. The
supernatant was pipetted into a mini-column and centrifuged for 30 seconds at 14,000
rpm to collect the plasmid DNA. After discarding the supernatant, 30L of TE was added
to the mini-column, and subsequently centrifuged for 1 minutes at 14,000 rpm. The
plasmid DNA was quantified with a BioDrop Duo UV/VIS Spectrophotometer (Denville
Scientific). The plasmids used in the study include IFN- firefly luciferase from provided
by J. Hiscott, McGill University, Montreal, Canada, Flag-MAVS and IRF3provided by
Fanxiu Zhu from Florida State University, Tallahassee, FL, Renilla TK and NF-𝜅B
firefly luciferase (Promega), pCI, Flag-tagged TBK-1 protein was a gift from Siddharth
Balachandran (Fox Chase Cancer Center, Philadelphia), and HA-MC160/pCI, HAMC160N/pCI, HA-MC160D1/pCI, HA-MC160D2/pCI, MC160C/pCI (Nichols and
Shisler, 2009).
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Cell Culture
Human Embryonic Kidney 293T (HEK 293T) cells, provided by ATCC, were
cultured in Dulbecco’s Modified Eagle’s Media (DMEM) supplemented with 10% fetal
bovine serum (FBS), and 1% penicillin and streptomycin. The cells were grown in a
250mL tissue culture flask, treated with vacuum gas plasma for consistent cell attachment
and growth, with vent cap, sterilized (VWR) and kept in a humidified incubator at 37C
with 5% CO2. Once 293T cells reached about 80% confluency, the media was aspirated
and the cells were washed with 3mLs of 1x phosphate buffered saline (PBS). The cells
were passaged with 2mLs of trypsin and 8mLs of DMEM with 10% FBS and diluted at a
ratio of 1:5 or 1:10.
Transfections and Luciferase Assays
HEK 293T were seeded at 2.5 × 105 cells per well on a tissue culture 12 well
plate (VWR) and kept in a humidified incubator at 37C. At 80% confluency, the cells
were transfected using pIFN- luciferase reporter gene, which is an enhancer that drives
firefly luciferase activity as well as the control reporter pRenilla-TK to drive sea pansy
luciferase activity. Plasmids obtained from minipreps were utilized for transfections.
100ng of Renilla TK, 200ng of IFN- luciferase reporter, and varying concentrations
ranging from 50ng-500ng of pFlag-MAVS or pTBK-1 and MC160 constructs (MC160,
MC160N, MC160D1, MC160D2, MC160C) for a total of 1g of DNA per well. For
transfections, the Mirus Trans-IT 2020 was used at a ratio of 3L/1g of total DNA,
along with 100uL of Opti-MEM (Gibco) per well. All transfections were repeated 3 times
each in triplicate.
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The cells were harvested at 16-24 hours post transfection using a DualLuciferase® Reporter Assay System (Promega) with 150L per well of 1x passive lysis
buffer on a rocker for 30 minutes at room temperature. After rocking, 10L of each lysate
was added to an opaque 96 well plate (Costar). Firefly luciferase activity was measured
by adding 50L of Luciferase Assay Reagent II. Luminescence was quantified using a
SpectraMax M5 reader and analyzed with SoftwareMax Pro. Following the firefly
quantification, 50L of 1x Stop & Glo® Reagent was added to the same plate and read to
quantify the Renilla values. The data was analyzed, averaged and normalized to obtain
the values of cells expressing pCI only to show relative fold change in IFN- luciferase
activity. A student t-test was performed to analyze statistical significance of each result (p
< 0.05).
Immunoblots
Lysates from luciferase assays were used for the immunoblotting. After
harvesting 293T cells with 1x passive lysis buffer, 130L of each lysate was added to a
1.5mL centrifuge tube, the samples consisted of pCI only, pFlag-MAVS or pFlag-TBK 1,
MC160, MC160N, MC160D1, MC160D2, and MC160C. The samples were centrifuged
for 1 minute at 14,000 rpm at 4C. 100L of the supernatant was collected for each
sample and added into a new 1.5mL centrifuge tube without disturbing the pellet. 20L
of 6x of sample buffer was added to each sample followed by 5% of 2-Mercaptoethanol.
The samples were boiled at 100C for 5 minutes. After boiling, the samples were placed
on ice for immediate use, or stored at -80C for later use.
Lysates were run on a 10% SDS-PAGE prepared in the laboratory. In the first
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well, 3L of the protein ladder (NEB) was loaded. In wells 2-10, 15L of each sample
was added to the corresponding well and the gel was run in 1X SDS-PAGE (0.25mM
Tris, 1.92mM glycine, 0.001% SDS, and deionized water) at 60 mA for 45 minutes. The
proteins were transferred to nitrocellulose paper at 90 volts for 1 hour with transfer buffer
(200mL methanol, 3.06g Tris, 14.39g glycine). After the transfer, the membrane was
either blocked for 1 hour at room temperature with gentle agitation or overnight at 4C in
5% milk (Bob’s Red Mill Non-Fat Dry Milk) dissolved in 1X Tris buffered saline with
Tween®20 (TBST).
After blocking, the membrane was probed with primary antibody (anti-HA or
anti-Flag, Sigma) diluted 1:1000 in 0.5% milk TBST for 1 hour at room temperature with
gentle agitation. The membrane was washed 3 times for 10 minutes each with 0.5% milk
TBST and subsequently probed with secondary antibody (goat-anti-mouse-HRP) diluted
1:5000 in 0.5% milk TBST for 1 hour at room temperature with gentle agitation. The
membrane was then washed 3 more times for 10 minutes each with 0.5% milk TBST.
The membrane was removed from the 0.5% milk TBST solution and patted dry. Bands
corresponding to flag-tagged or HA-proteins were visualized by chemiluminescence
using the SuperSignal™ West Femto (ThemoScientific) reagent, following the
manufacturer’s protocol. The blots were imaged using a FluorChem E system and saved
for further analysis.
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Results
MC160 Inhibits MAVS-mediated IFN- activation
Because MCV cannot replicate in tissue culture, the MC160 wild-type and mutant
MC160 expression vectors were transfected into HEK 293T cells. Both MC159 and
MC160 proteins inhibit MAVS-mediated activation of the IFN- enhancer (Randall et
al., 2013). The mechanism by which MC159 impedes innate immune responses is well
studied. However, the molecular mechanism by which MC160 expression antagonizes
MAVS signaling remains undetermined. Randall et al. reported the second DED of
MC160 was dispensable for inhibiting IRF3 activation (Randall et al., 2013). Because the
IFN--enhancer element contains binding sites for multiple transcription factors
including NF-𝜅B, IRF3 and IRF7 (J. Hiscott, McGill University, Montreal, Canada), the
goal of this study was to determine the region of the MC160 protein necessary to inhibit
MAVS-mediated IFN- activation.
Previously, mutagenesis was performed on the MC160 protein to divide the full
length protein into individual regions composed of an N-terminal region (residues 1-220),
a C-terminal region (residues 224-371) and the two individual DEDs (residues 5-79 for
DED1 and 97-175 for DED2) (Figure 2). Each region was engineered with an HA-tag on
the N-terminal regions to confirm protein expression via immunoblot (Nichols and
Shisler, 2009). In the current study, 293T cells were transiently transfected with varying
concentrations of pHA-MC160 mutants, as well as pMAVS, pIFN--luc and Renilla
enhancer in each well. 16-24 hours post transfection, the cells were lysed and analyzed
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using a dual-reporter assay where the firefly luciferase gene was under the transcriptional
control of the IFN- enhancer (J. Hiscott, McGill University, Montreal, Canada).
A MAVS expression plasmid was overexpressed in 293T cells using 400ng of
pMAVS, 300ng of MC160 constructs and 300ng of the reporter genes (200ng IFN and
100ng Renilla TK). Expression of either wild type MC160 or MC160N resulted in
approximately a 54-fold and 15-fold decrease in IFN- activity, respectively, when
compared to cells expressing the empty vector pCI and MAVS. Although MC160C
expression did not inhibit to the same degree as MC160 or MC160N, relative to pCI cotransfected with MAVS, expression of MC160C showed a decrease of IFN- luciferase
activity roughly 2.3 fold. Interestingly, MC160DED1 and MC160DED2 did not inhibit
IFN- enhancer controlled luciferase activity when MAVS was overexpressed compared
to MC160 and MC160N. A mixing experiment was conducted to evaluate whether the
co-expression of MC160D1 and MC160D2 could inhibit IFN activity as well as MC160N
expression, but when expressed together as separate proteins, there was no inhibition in
IFN- enhancer controlled luciferase activity (Figure 3). The presence of MC160
constructs and the flag-tagged MAVS protein in the lysates was confirmed via
immunoblot utilizing anti-FLAG and anti-HA (Figure 4). MAVS expression was
confirmed in every sample, as well as expression of each MC160 construct. The
MC160D1 protein expressed a much lighter band compared to all other mutants.
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MAVS-induced luciferase
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Figure 3: The effect of MC160 truncation mutants on IFN luciferase activity in the
presence of higher concentrations of MAVS. Subconfluent 293T cells were transfected
with pIFN-luc (200ng); pRenilla-TK (100ng); pMAVS (400ng); and MC160 constructs
(300ng) (D1/D2 mixing experiment had 150ng of D1 and 150ng of D2). 16-24 hours post
transfection the cells were lysed and firefly and sea pansy luciferase activities were
recorded. Luciferase data was determined based on the ratio of firefly to sea pansy
luciferase values. All values were normalized to cells expressing the reporters and the
empty vector. Values are shown as mean ± standard deviations (SD). All experiments
were performed in triplicate, n=3. *Statistical significance was determined by a p < 0.05.
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Figure 4: Expression of Flag-MAVS and HA-tagged MC160 proteins. Membranes were
probed with anti-HA (1:1000) and anti-Flag (1:1000) antibodies. Bands corresponding to
Flag-MAVS or the indicated MC160 mutant protein were visualized by
chemiluminescence.
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A similar MAVS experiment was conducted with a lower concentration of MAVS
and higher concentrations of MC160 constructs. 293T cells were transfected with 200ng
of IFN- enhancer luciferase gene, 100ng of Renilla TK, 200ng of MAVS and 500ng of
MC160 constructs. Again the MC160N protein, which contains both DEDs, inhibited
IFN- enhancer controlled luciferase activity compared to pCI stimulated with MAVS.
MC160C expression also inhibited MAVS-induced activation of on the IFN- enhancer
controlled luciferase activity when compared to pCI co-transfected with MAVS.
However, IFN- luciferase activation was about 2.9-fold higher in lysates expressing
MC160C than in MC160N. Even when transfected at higher concentrations, MC160D1
did not inhibit activation of IFN- luciferase activity (Figure 5). In this experiment, when
we transfected with higher amounts of MC160D2 relative to lower amounts of MAVS,
we observed slight inhibition of IFN- luciferase activity, but not to the levels seen with
MC160N expressing cells. Expression of MC160 mutants were verified via immunoblot
(Figure 6). Interestingly, in this experiment the MC160D2 protein was detected at levels
similar to the MC160N protein. Therefore, it seemed unlikely that expression levels of
MC160D2 contributed to less inhibition of MAVS-induced IFN- luciferase activity
relative to the inhibition observed in MC160N expressing cells. Taken together, the data
suggests both MC160 DEDs are required to inhibit MAVS-induced IFN-β activation.
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Figure 5: The effect of MC160 truncation mutants on IFN- luciferase activity in the
presence of lower concentrations of MAVS. Sunconfluent 293T cells were transiently
transfected with pIFN--luc (200ng); pRenilla-TK (100ng); pMAVS (200ng); and
MC160 constructs (500ng). The results were collected using a dual-luciferase reporter
assay. IFN- enhancer gene controls firefly luciferase activity, while Renilla drives the
sea pansy luciferase activity. Luciferase data was determined based on the ratio of firefly
to sea pansy luciferase values. All values were normalized to cells expressing the
reporters and the empty vector. Values are shown as mean ± standard deviations (SD).
All experiments were performed in triplicate, n=3. *Statistical significance was
determined by a p < 0.05.
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Figure 6: Immunoblots were used to verify the presence of MC160 constructs and
MAVS in the lysates. MAVS was detected by using a FLAG antibody (1:1000), while
MC160 mutants were detected by an HA antibody (1:1000). (**D2 samples were loaded
twice).
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MC160 Inhibits TBK-1-mediated IFN- Activation
During infection, MAVS recruits TBK-1 to complex with IKK𝜀 at the
mitochondria. The TBK-1/ IKK𝜀 phosphorylates transcription factors IRF3 and IRF7,
which eventually leads to IFN- production (Sharma et al., 2003). To this end, it was of
interest to investigate which region(s) of the MC160 protein is/are crucial to maintain
proficiency in dampening TBK-1-mediated type I IFN activation in hosts. In the first
TBK-1 experiment, 293T cells were transiently transfected with 400ng of pTBK-1,
300ng of MC160 constructs, 200ng of pIFN--luc and 100ng of pRenilla-TK. MC160
constructs containing both DEDs, MC160 and MC160N, inhibited activation of the IFN enhancer regulated luciferase by approximately 378.78-fold and 11.64-fold difference,
respectively compared to pCI transfected cells overexpressing pTBK-1. However,
MC160D1, MC160D2 and MC160C failed to inhibit TBK-1 induced activation of IFN-β.
(Figure 7). This result was surprising given that Randall et al. previously reported both
MC160D1 and MC160C blocked TBK-1 induced activation of IRF3 (Randall et al.,
2013). The expression levels for the corresponding immunoblot are consistent. FladTBK-1 was detected in all the samples. Again, the wild-type MC160 protein and
MC160N are expressed very well. MC160C expression is also very abundant however
D2 was very faint and D1 was undetectable in this sample (Figure 8).
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Figure 7: The effect of MC160 truncation mutants on TBK-1-mediated IFN- enhancer
controlled luciferase activation. TBK-1 was expressed at a greater concentration than the
MC160 constructs. 293T cells were transfected with pIFN--luc (200ng); pRenilla-TK
(100ng); pTBK-1 (400ng); and MC160 mutants (300ng). 16-24 hours post transfection
the cells were lysed and firefly and sea pansy luciferase activities were recorded.
Luciferase data was determined based on the ratio of firefly to sea pansy luciferase
values. All values were normalized to cells expressing the reporters and the empty vector.
Values are shown as mean ± standard deviations (SD). All experiments were performed
in triplicate, n=3. *Statistical significance was determined by a p < 0.05.
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Anti- Flag

Anti-HA

Figure 8: Expression of Flag-TBK-1 and HA-tagged MC160 proteins, probed with antiHA (1:1000) and anti-Flag (1:1000) antibodies in 0.5% milk TBST for 1 hour. Bands
corresponding to Flag-TBK-1 or the indicated MC160 mutant protein were visualized by
chemiluminescence.
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A second TBK-1 study was performed to assess the effects of less TBK-1 and
more MC160 mutants on IFN- enhancer controlled luciferase activity. 293T cells were
transiently transfected with 200ng of pIFN--luc, 100ng of pRenilla-TK, 200ng of
pTBK-1 and 500ng of MC160 constructs. Expression of MC160 inhibited IFN-
enhancer controlled luciferase activity about 86.3-fold better than pCI co-transfected with
TBK-1. Similarly, MC160N expression on IFN- enhancer controlled luciferase activity
was approximately 15-fold lower when compared to pCI with TBK-1. MC160C inhibited
activation of IFN-, but not as strong as either MC160 or MC160N. Neither
MC160D1nor MC160D2 inhibited IFN- activation when compared to cells transfected
with the empty vector and TBK-1 plasmids (Figure 9). These finding were unanticipated
as Randall et al. reported that all MC160 mutants, except MC160D2, inhibited TBK-1induced IRF3 activation (Randall et al., 2013). A corresponding immunoblot to verify
expression of the MC160 constructs in the lysates was conducted (Figure 10). Flag-TBK1 is present in all samples. However, the sample containing the MC160 protein seemed to
show a lower amount of TBK-1 compared to all other samples. MC160C protein levels
are very high and are similar to wild type MC160. MC160N protein expressed a band
comparable to the band associated with MC160D2, indicating similar protein levels.
While MC160D1 showed a very faint band compared to all the other constructs.
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Figure 9: The effect of MC160 truncation mutants on IFN- luciferase activity in the
presence of lower concentrations of TBK-1. MC160 constructs and TBK-1 were
overexpressed in 293T cells (500ng and 200ng, respectively) along with pIFN--luc
(200ng); and p-Renilla-TK (100ng). Data was obtained based on the ratio of firefly to sea
pansy luciferase values. The values were normalized to cells expressing the reporters and
the empty vector. Values are shown as mean ± standard deviations (SD). All experiments
were performed in triplicate, n=3. *Statistical significance was determined by a p < 0.05.
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Figure 10: Expression of Flag-TBK-1 and HA-tagged MC160 proteins. Lysates were run
on an SDS-PAGE and proteins were subsequently transferred to a nitrocellulose
membrane. The membranes were probed with anti-HA (1:1000) and anti-Flag (1:1000)
antibodies in 0.5% milk TBST for 1 hour. Bands corresponding to Flag-TBK-1 or the
indicated MC160 mutant protein were visualized by chemiluminescence.
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MC160 Titrations expressed with MAVS or TBK-1
The overexpression of MC160 or MC160N, both of which have the tandem DEDs
together on one protein, inhibited MAVS- and TBK1 induced IFN- enhancer controlled
luciferase activity (Figure 3 through Figure 7). While MC160C expression inhibited IFN enhancer controlled luciferase activity in most cases, it was never comparable to the
inhibition seen when MC160 or MC160N were expressed. In contrast, the luciferase data
revealed no statistically significant inhibition in IFN- enhancer controlled luciferase
activity when MC160D1 or MC160D2 were overexpressed with either MAVS or TBK-1.
Although the degree of IFN- luciferase activity varied among MC160D1, MC160D2,
and MC160C, none displayed levels comparable to MC160 or MC160N, which were
both statistically significant compared to the empty vector co-transfected with either
TBK-1 or MAVS. However, one concern was that based on immunoblots, neither
MC160D1 nor MC160D2 seemed to express consistently to the same level as MC160
full-length or MC160N, potentially due to protein insolubility or inability of the protein
to fold correctly. However, further studies are needed to determine that reasoning.
Therefore, one possible explanation as to why neither D1 nor D2 inhibited could be due
to lower protein levels in the cells. To this end, a titration of the MC160 mutant
expression plasmids was conducted with either MAVS or TBK-1.
MC160 mutants were transiently transfected into 293T cells at the indicated
concentrations with MAVS or TBK-1 at 200ng. Because MC160N produced such a
strong inhibitory effect on IFN- luciferase activity, a low concentration of 50ng and a
high of 100ng of MC160N were tested. The luciferase data showed approximately a 3.8-
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fold and 5.88-fold difference between MC160N expressed at 50ng or 100ng, respectively,
when compared to pCI with MAVS (Figure 11). Similarly, MC160N expressed at 50ng
or 100ng with 200ng of TBK-1 was roughly 3.66- and 5.57-fold less compared to the
empty vector pCI co-transfected with TBK-1 (Figure 13). Upon analyzing the D1 and D2
titrations, with a low of 100ng and a high of 500ng, neither DED inhibited MAVS or
TBK-1 induced IFN- enhancer controlled luciferase activity (Figure 11, Figure 13). The
lysates for each titration were run on an SDS-PAGE, and blotted with anti-FLAG and
anti-HA to validate the luciferase results for titrations with MAVS and TBK-1,
respectively (Figure 12, Figure 14). For the titration with MAVS, only MC160N
expressed at 50ng and 100 ng inhibited IFN- enhancer controlled luciferase activity,
while neither DED at 100ng or 500ng inhibited IFN- luciferase activity. Confirming
MC160 mutant protein expression via immunoblot showed that the D1 and D2 protein
expression at 500ng transfection had more similar protein levels to the MC160N protein
at 50ng. These results suggest that the decreased protein levels in D1 and D2 are not
correlated to the inability to inhibit MAVS-induced IFN- enhancer controlled luciferase
activity (Figure 12). Likewise, the MC160 titration with TBK-1 showed that MC160N
expressed at 50ng and 100ng inhibited IFN- luciferase activation, while all other
mutants at various concentration did not. Surprisingly, D1 expressed at 500ng increased
IFN- enhancer controlled luciferase activity by approximately 1.67-fold compared to the
pCI co-transfected with TBK-1 (Figure 13). The enhanced expression of luciferase
activity could be due to binding to procaspase-8 through MC160 DEDs. Procaspase-8
when converted to caspase-8 results in disassembly of the MAVS-complexes in order to

29

limit duration and intensity of signaling (Rajput et al., 2011). Whether, MC160D1 when
expressed independently binds and interferes with this caspase-8 function is under
investigation. The immunoblot measuring the titration of MC160 protein expression with
TBK-1 showed good expression of MC160N at 50ng and 100ng. However, D1 levels
were hardly detectable, even at 500ng. Interestingly, the protein levels for D2 at 100ng
and 500ng were more similar to MC160N protein levels at 50 ng (Figure 14). Based on
the collected data, there does not seem to be a correlation between protein expression and
inhibition of IFN- firefly luciferase activity.
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Figure 11: The effect of MC160 mutant titrations on IFN luciferase activity in the
presence of MAVS. Subconfluent 293T cells were transfected with pIFN-luc (200ng);
pRenilla-TK (100ng); pMAVS (200ng); and MC160 constructs at varying concentrations.
MC160N inhibits IFN activity at concentrations as low as 50ng. Neither DED showed
inhibition of IFN- activity, despite increasing amounts of MC160 mutant. Values are
shown as mean ± standard deviations (SD) (n=3). *Statistical significance was
determined by a p < 0.05.
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Figure 12: Expression of Flag-MAVS and HA-tagged MC160 proteins titrations.
Membranes were probed with anti-HA (1:1000) and anti-Flag (1:1000) antibodies. Bands
corresponding to Flag-MAVS or the indicated MC160 mutant protein were visualized by
chemiluminescence.
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Figure 13: The effect of MC160 truncation mutants on IFN luciferase activity in the
presence of TBK-1. 293T cells were transfected with pIFN-luc (200ng); pRenilla-TK
(100ng); pTBK-1 (200ng); and MC160 constructs at varying concentrations. MC160N
inhibits IFN activity at concentrations as low as 50ng. Neither DED showed inhibition
of IFN- activity, despite increasing amounts of MC160 mutants. Values are shown as
mean ± standard deviations (SD) (n=3). *Statistical significance was determined by a p <
0.05.
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Figure 14: MC160 titration with TBK-1 expression immunoblot. Confirmation of
MC160 mutant expressions are shown here. The membrane was probed with primary
antibodies, anti-FLAG (1:1000) and anti-HA (1:1000), followed by a secondary antibody,
goat-anti-mouse-HRP (1:5000) each for 1 hour at room temperature. Protein expression
was visualized by chemiluminescence.
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Discussion
MC159 and MC160 proteins were previously identified as viral proteins that
inhibit MAVS-mediated IFN activation (Randall et al. 2013). The purpose of this thesis
was to identify the region of the MC160 protein required to inhibit activation of type I
IFNs. While Randall et al. presented evidence that all MC160 constructs with the
exception of MC160D2 inhibit TBK-1 induced activation of IRF3 (Randall et al., 2013),
our data suggests inhibition of TBK-1 or MAVS-induced IFN- luciferase activity is
exclusive to MC160 and MC160N, with MC160C showing partial inhibition of IFN-
under certain conditions. Thus, the data presented here suggest that MC160 requires both
DEDs to inhibit TBK-1 or MAVS-induced IFN- activation.
One possible explanation as to why the MC160N protein inhibits activation of
IFN-β and the D1 and D2 mutants do not could be attributed to expression levels. When
MC160N, D1, and D2 expression vectors were transfected at equal concentrations of
plasmid DNA, bands corresponding to MC160N in immunoblots was often detected at
higher concentrations relative to D1 and D2 (Figures 4, 6, 8 and 10). However, this
explanation seems unlikely for several reasons. 1) When the MC160N expression vector
was transfected at as little as 50ng of plasmid DNA, MC160N still strongly inhibited
relative to 500 ng of MC160D1 and MC160D2. 2) Based on the immunoblots for each
titration experiment, protein levels of MC160N at 50ng was more comparable to
MC160D1 at 500ng when MAVS was overexpressed (Figure 12). 3) MC160D2 at 500 ng
does not inhibit activation of type I IFNs, but does prevent activation of TNF-induced
NF-κB activation (Nichols and Shisler 2009). 4) MC160D1 inhibits TBK-1 induced IRF3
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activation (Randall et al., 2013) when transfected at equal concentrations to that used in
in the experiments presented herein. Therefore, the most likely explanation of the results
is that MC160 requires both DEDs to inhibit activation of type I IFNs. Further, when
MC160D1 and MC160D2 were co-transfected in cells to determine if individual DEDs
mixed together could inhibit TBK-1 or MAVS-induced IFN- luciferase activity to levels
similar to MC160N, MC160D1 and MC160D2 failed to inhibit under these conditions
(Figure 3). Thus, both DEDs are required to be on the same protein to inhibit TBK-1 or
MAVS-induced IFN- enhancer controlled luciferase activity.
While MC160C partially inhibited MAVS and TBK-1-induced IFN- luciferase
activation, it was not to the same degree as the regions containing both DEDs. MC160C
expression was detected at higher concentrations than wild-type MC160 or MC160N.
Thus, reduced inhibition of activation of IFN-β by MC160C cannot be attributed to
differences in expression levels. Interestingly, MC160C binds to Hsp90 (Nichols and
Shisler, 2009). During virus infection, Hsp90 forms a bridge between IRF3 and TBK-1,
thereby stabilizing the interaction and enabling a better signal through the pathway (Yang
et al., 2006). Perhaps, MC160C when expressed at higher amounts than TBK1, competes
with TBK1 for binding to MAVS signaling complexes, but when TBK1 is at higher
levels than MC160C, TBK1 outcompetes MC160C for binding to MAVS complexes.
In conclusion, the MCV MC160 protein inhibits MAVS-mediated signaling
through interactions mediated by the MC160 DEDs. The future experiments of this
project would be to identify the cellular binding partner of MC160. We surmise that the
MC160 protein inhibits the MAVS signaling pathway at the TBK-1 level, therefore
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running co-immunoprecipitations with Flag-TBK-1 would be advantageous.
Additionally, running a yeast two-hybrid system using MC160 and TBK-1 would be
useful in determining the binding partner of MC160 protein in the MAVS pathway.
Another future direction would be to investigate whether MC160 expression can block
activation of TBK-1 induced by other pathways. We have preliminary data showing LPS
induced phosphorylation of TBK-1 in RAW 264.7 cells (Figure 15). RAW 264.7 cells
could be transfected with the MC160 constructs and treated with LPS, which signals
through TLR4, eventually leading to the translocation of NF-𝜅B and IRF3 into the
nucleus, thus inducing IFN production. Similarly, instead of LPS, treatment with Poly
I:C, a synthetic mimic of dsRNA produced during viral infections, would signal through
TLR3, thus inducing IFN production. MC160 inhibits phosphorylation of TBK-1 induced
by the overexpression of TBK-1 (Randall et al., 2013), therefore TBK-1 phosphorylation
would not be excepted in cells expressing MC160.
Because MCV cannot replicate in either tissue culture or animal models,
overexpressing viral proteins by transfecting 293T cells was appropriate to study the
effects of MC160 expression on MAVS-mediated activation of type I IFNs. To validate
that MC160 functions similarly during a live virus infection, recombinant vaccinia
viruses could be used as a surrogate virus to express and study MC160 in the context of a
virus infection.
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Figure 15: LPS induced TBK-1 phopsorylation of RAW 264.7 cells. The vehicle consists
of 2% dimethyl sulfoxide (DMSO) diluted in PBS. LPS is detected by TLR4 and signals
down the pathway to activate type I IFNs. Treating MC160 constructs with LPS would
verify the ability of the MC160 protein to inhibit TBK-1 phosphorylation in this pathway.
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